ANA Provides International Transportation for COVID-19 Vaccine through COVAX Facility

2021.08.25

ANA cooperated with long-term partner Scan Global Logistics to facilitate the delivery of COVID-19 vaccines manufactured in Japan to Cambodia, Bangladesh, Sri Lanka Laos, East Timor, Fiji, and Maldives through the Japanese government's cooperation with the COVAX facility
Since 2017, ANA has been certified by IATA's Center of Excellence for Independent Validators in Pharmaceutical Logistics (CEIV Pharma)

TOKYO, Aug. 25, 2021 - All Nippon Airways (ANA), Japan's largest and 5-Star airline for eight consecutive years has partnered with the global transport and logistics provider Scan Global Logistics for the international transportation of COVID-19 vaccines manufactured in Japan to Cambodia, Bangladesh, Sri Lanka, Laos, East Timor, Fiji, and Maldives through the Japanese government's cooperation with the COVAX facility.

The COVAX Facility is a logistical hub designed to maximize resource mobilization and supply coordination led by Gavi, the global vaccine alliance leading COVAX efforts. The initiative aims to secure equitable access to vaccines worldwide regardless of income levels and increasing availability in developing nations throughout Southeast Asia is key to this strategy. By utilizing the COVAX facility, ANA is able to contribute to making COVID-19 vaccines swiftly available at an affordable price, leveraging economies of scale through guaranteeing purchase and market demand for vaccine.

The transportation of vaccines presents a number of logistical hurdles, requiring ANA to leverage its full range of expertise and experience gained at the forefront of cargo transportation. Despite the challenges, ANA has an exceptional track record in the delivery of pharmaceutical goods and has established a reliable and efficient operational structure for the global delivery of vaccines and other crucial medical supplies. In addition, ANA has been certified by IATA's Center of Excellence for Independent Validators in Pharmaceutical Logistics (CEIV Pharma) since 2017, making it the first Japanese airline to receive this distinction.

As part of its efforts to make flying safer, ANA has instituted the ANA Care Promise, a comprehensive series of protocols designed to prevent the spread of COVID-19. As the COVID-19 pandemic continues to affect nearly every aspect of life, ANA remains committed to doing all it can to empower healthcare workers and public health professionals worldwide.

About ANA
Founded in 1952 with just two helicopters, All Nippon Airways (ANA) has grown to become the largest airline in Japan. ANA HOLDINGS Inc. (ANA HD) was established in 2013 as the largest airline group holding company in Japan, comprising 71 companies including ANA and Peach Aviation, the leading LCC in Japan.

ANA is a launch customer and the largest operator of the Boeing 787 Dreamliner, making ANA HD the biggest Dreamliner owner in the world. A member of Star Alliance since 1999, ANA has joint venture agreements with United Airlines, Lufthansa German Airlines, Swiss International Airlines, Austrian Airlines and Brussels Airlines - giving it a truly global presence.

The airline's legacy of superior service has helped it earn SKYTRAX's respected 5-Star rating every year since 2013, with ANA being the only Japanese airline to win this prestigious designation for eight consecutive years. ANA also has been recognized by Air Transport World as "Airline of the Year" three times (2007, 2013 and 2018); it is one of only a select few airlines to win this prominent award multiple times.

ANA is the only company in the aviation industry to receive the Gold Class distinction from the 2021 S&P Global Sustainability Awards and ANA HD has been selected as a member of the Dow Jones Sustainability World Index list for the fourth consecutive year and the Dow Jones Sustainability Asia Pacific Index list for the fifth consecutive year.

For more information, please refer to the following link:
https://www.ana.co.jp/group/en/

ANA Provides International Transportation for COVID-19 Vaccine through COVAX Facility.pdf